Home > Insider Trading > Filing (0000899243-15-002783)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631650	Aimmune Therapeutics Inc.	AIMT	Pharmaceutical Preparations (2834)	452748244

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1253886	G Patrick Enright	C/O Longitude Capital Partners Ii, Llc 800 El Camino Real, Suite 220 Menlo Park CA 94025	Yes	No	Yes	No
1431159	Juliet Bakker Tammenoms	C/O Longitude Capital Partners Ii, Llc 800 El Camino Real, Suite 220 Menlo Park 94025	No	No	Yes	No
1527510	Longitude Venture Partners Ii, L.p.	C/O Longitude Capital Partners Ii, Llc 800 El Camino Real, Suite 220 Menlo Park CA 94025	No	No	Yes	No
1647491	Longitude Capital Partners Ii, Llc	800 El Camino Real Suite 220 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2015-08-11	3,873,530	$0.00	3,873,530	No	4	C	Indirect	By: Longitude Venture Partners II, L.P.
Common Stock, $0.0001 Par Value	Acquisiton	2015-08-11	3,248,600	$0.00	7,122,130	No	4	C	Indirect	By: Longitude Venture Partners II, L.P.
Common Stock, $0.0001 Par Value	Acquisiton	2015-08-11	312,500	$16.00	7,434,630	No	4	P	Indirect	By: Longitude Venture Partners II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By: Longitude Venture Partners II, L.P.
No	4	C	Indirect	By: Longitude Venture Partners II, L.P.
No	4	P	Indirect	By: Longitude Venture Partners II, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2015-08-11	3,873,530	$0.00	3,873,530	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2015-08-11	3,248,600	$0.00	3,248,600	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis immediately prior to the closing of Issuer's initial public offering.
This report is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital II as general partner of Longitude Venture II maybe deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are each managing members of Longitude Capital II and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Reporting Persons. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
Longitude Capital II purchased an additional 312,500 shares of Issuer's common stock in connection with the initial public offering at the offering price of $16.00 per share.
The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock have no expiration date.